Treatment with [177Lu]Lu-PSMA-617 is not recommended in patients with moderate-to-severe renal impairment with baseline CrCl <50 mL/min or end-stage renal disease, as the pharmacokinetic profile and the safety of [177Lu]Lu-PSMA-617 have not been studied in these patients (94). Here, FOLH1 is linked to chronic kidney disease.